Day One Biopharmaceuticals (DAWN) Enterprise Value: 2022-2025
Historic Enterprise Value for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to $270.6 million.
- Day One Biopharmaceuticals' Enterprise Value fell 59.26% to $270.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 billion, marking a year-over-year decrease of 210.78%. This contributed to the annual value of $746.0 million for FY2024, which is 17.52% down from last year.
- According to the latest figures from Q3 2025, Day One Biopharmaceuticals' Enterprise Value is $270.6 million, which was up 31.50% from $205.8 million recorded in Q2 2025.
- In the past 5 years, Day One Biopharmaceuticals' Enterprise Value ranged from a high of $1.2 billion in Q4 2022 and a low of $205.8 million during Q2 2025.
- Moreover, its 3-year median value for Enterprise Value was $664.1 million (2024), whereas its average is $623.0 million.
- In the last 5 years, Day One Biopharmaceuticals' Enterprise Value spiked by 93.39% in 2024 and then crashed by 75.57% in 2025.
- Over the past 4 years, Day One Biopharmaceuticals' Enterprise Value (Quarterly) stood at $1.2 billion in 2022, then fell by 27.09% to $904.5 million in 2023, then decreased by 17.52% to $746.0 million in 2024, then plummeted by 59.26% to $270.6 million in 2025.
- Its Enterprise Value stands at $270.6 million for Q3 2025, versus $205.8 million for Q2 2025 and $330.7 million for Q1 2025.